It's not just specialty drugmakers raising prices in recent days. Big Pharma has pushed through a spate of increases, and while all of them are sub-10%—the cap some companies have adopted—some of them will cost payers and consumers plenty.
BioNTech has raised $270 million (€224 million). The series A round positions the German biotech to mount a multifront attack on cancer, spearheaded by mRNA therapies and supported by a clutch of other modalities including CAR-T cells.
An innovative device for measuring the change of the femur position during hip replacement surgery has been built by scientists from Lodz University of Technology. Its use shortens the time of surgery and gives better chance that patients after surgery will not have problems with walking.
Smaller, smarter, more efficient and prettier…. Wearables are becoming increasingly more popular. Where first only sport fanatics and early tech adopters were interested, we now see that the high tech wearable devices become more common and accepted.
A study released in October 2017 found EHR (electronic health records) use has been listed as a contributing factor to patient injury at an increased rate over the past decade. Poorly-designed EHR systems combined with human error have resulted in patient safety problems in an increasing number of malpractice claims from 2007-2016.
Scholar Rock has raised $47 million to take its treatment for spinal muscular atrophy (SMA) into the clinic. The series C tees up Scholar Rock to find out whether its myostatin blocker can best the underwhelming performance of one-time rivals from companies including Novartis.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.